BiotechTube
BCN Biosciences

BCN Biosciences

San Diego, United States· Est.
bcnbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $34.4M

Overview

BCN Biosciences is a preclinical biotech firm targeting high-need oncology segments, specifically KRAS-driven cancers (G12D, G12V) and immune checkpoint regulation via small molecules. The company differentiates itself through a novel mechanism aimed at restoring PTEN expression to combat KRAS mutations and a unique approach to modulating PD-1 in the tumor microenvironment. Founded in 2009, BCN has secured non-dilutive funding through SBIR grants and BARDA contracts, positioning its lead programs for potential partnership and advancement into clinical trials.

Oncology

Technology Platform

Novel small molecule discovery platform targeting oncogenic pathways (e.g., RAS via PTEN restoration) and immune checkpoint modulation (e.g., PD-1 expression).

Funding History

13
Total raised:$34.4M
Grant$1.0M
Grant$1.0M
Series A$20M
Grant$300K

Opportunities

The significant unmet need in non-G12C KRAS-mutant cancers (e.g., pancreatic, colorectal) presents a major commercial opportunity if BCN's novel PTEN-restoration mechanism proves effective.
Additionally, developing an oral small molecule for PD-1 regulation could capture a segment of the large immuno-oncology market by offering a more convenient and potentially cheaper alternative to antibody therapies.

Risk Factors

The primary risks are the high technical risk associated with novel, unproven mechanisms of action and the funding risk inherent to a preclinical, private company.
BCN also faces intense competition from large pharmaceutical firms with substantial resources in both the RAS and immuno-oncology spaces.

Competitive Landscape

In KRAS, BCN competes against companies like Amgen, Mirati (Bristol Myers Squibb), and Revolution Medicines, which have advanced direct inhibitors, primarily for G12C. BCN's PTEN-focused approach is differentiated but unvalidated. In PD-1 regulation, it faces the entire established market of PD-1/PD-L1 blocking antibodies (e.g., Keytruda, Opdivo) and emerging small molecule programs from other biotechs.

More companies in Small Molecule Drugs →More companies in United States →